Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Squamous Cell Carcinoma
DRUG: Afatinib 40 MG
Overall Response Rate, Overall response rate (ORR) as defined by proportion of patients who have achieved a complete or partial response per RECIST 1.1 criteria, Up to 1 Year
Progression free survival, Progression free survival, defined as the time from first dose to the earlier date of assessment of progression or death by any cause in the absence of progression, Up to 5 Years|Overall survival, Overall survival, as measured from the date of first dose to the date of death by any cause, Up to 5 Years|Treatment-related adverse events, Treatment-related adverse events per NCI CTCAE v5 criteria, Up to 40 days after end of treatment
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.